PMID- 31418344
OWN - NLM
STAT- MEDLINE
DCOM- 20200525
LR  - 20200525
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 17
IP  - 5
DP  - 2019
TI  - What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic 
      Steatohepatitis?
PG  - 425-428
LID - 10.2174/157016111705190703102816 [doi]
AB  - Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is 
      characterized by accumulation of fat (>5% of the liver tissue), in the absence of 
      alcohol abuse or other chronic liver diseases. Its prevalence is increasing 
      because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD 
      can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis 
      (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, 
      Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality 
      in NAFLD/NASH patients. Current guidelines suggest the use of pioglitazone both 
      in patients with T2DM and in those without. The newer antidiabetic drugs such as 
      Glucagon Like Peptide-1 Receptor Agonists (GLP-1 RA), Sodium-Glucose co- 
      Transporter-2 inhibitors (SGLT2i), and statins plus ezetimibe, are considered 
      safe by the guidelines, and may have a beneficial effect on NAFLD/NASH as well as 
      Cardiovascular Disease (CVD) morbidity and mortality. Future drugs seem to have a 
      potential for holding down the evolution of NAFLD and reduce liver- and 
      CVD-related morbidity and mortality, but they will take some years to be approved 
      for routine use. Until then pioglitazone, GLP-1 RA, SGLT2i, and statins plus 
      ezetimibe, especially in combination might be useful for treating the huge number 
      of patients with NAFLD/NASH.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Doumas, Michael
AU  - Doumas M
AD  - VAMC and George Washington University, Washington, DC, United States.
FAU - Imprialos, Konstantinos
AU  - Imprialos K
AD  - VAMC and George Washington University, Washington, DC, United States.
AD  - 2nd Prop. Department of Internal Medicine, Hippocration Hospital, Medical School 
      of Aristotle University Thessaloniki, Thessaloniki, Greece.
FAU - Stavropoulos, Konstantinos
AU  - Stavropoulos K
AD  - VAMC and George Washington University, Washington, DC, United States.
AD  - 2nd Prop. Department of Internal Medicine, Hippocration Hospital, Medical School 
      of Aristotle University Thessaloniki, Thessaloniki, Greece.
FAU - Athyros, Vasilios G
AU  - Athyros VG
AD  - VAMC and George Washington University, Washington, DC, United States.
AD  - 2nd Prop. Department of Internal Medicine, Hippocration Hospital, Medical School 
      of Aristotle University Thessaloniki, Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - EOR26LQQ24 (Ezetimibe)
SB  - IM
MH  - Anticholesteremic Agents/adverse effects/*therapeutic use
MH  - Diffusion of Innovation
MH  - Drug Therapy, Combination
MH  - Ezetimibe/adverse effects/*therapeutic use
MH  - Forecasting
MH  - Gastroenterology/*trends
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Liver/*drug effects/metabolism/pathology
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy/metabolism/mortality/pathology
MH  - Prevalence
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - Treatment Outcome
OTO - NOTNLM
OT  - GLP1 RA
OT  - Non-alcoholic fatty liver disease (NAFLD)
OT  - SGLT2i
OT  - ezetimibe
OT  - non-alcoholic steatohepatitis (NASH)
OT  - perspective
OT  - pioglitazone
OT  - statins.
EDAT- 2019/08/17 06:00
MHDA- 2020/05/26 06:00
CRDT- 2019/08/17 06:00
PHST- 2019/08/17 06:00 [entrez]
PHST- 2019/08/17 06:00 [pubmed]
PHST- 2020/05/26 06:00 [medline]
AID - CVP-EPUB-99360 [pii]
AID - 10.2174/157016111705190703102816 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2019;17(5):425-428. doi: 10.2174/157016111705190703102816.